RecruitingNot ApplicableNCT03926520

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Effect and Safety of Electroconvulsive Therapy Plus Usual Care for the Acute Management of Severe Agitation in Dementia


Sponsor

Brent Forester

Enrollment

50 participants

Start Date

Jan 28, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.


Eligibility

Min Age: 40 Years

Inclusion Criteria11

  • Diagnosis of Dementia, of the following subtypes,
  • Alzheimer's dementia, according to NIA-AA Criteria for dementia
  • Vascular dementia based on:
  • i. History consistent with insidious onset of illness and gradual clinical decline ii. MRI evidence of microvascular ischemic disease (microinfarcts) iii. Physical and neurological examination do not indicate current or prior stroke c. Frontotemporal dementia d. Dementia with Lewy Bodies
  • Mini Mental Status Exam (MMSE) less than or equal to 15
  • Cohen-Mansfield Agitation Inventory Nursing Home Version (CMAI) score of 5 or more on at least one item or score of 4 on two items of aggression or physical nonaggression that holds potentially dangerous consequences including hitting (including self), kicking, grabbing onto people, pushing, throwing things, biting, scratching, spitting, hurting self or other, tearing things or destroying property, making physical sexual advances, trying to get to a different place, or intentional falling (items 1-11, 14, 15) OR one score of 5 or more in items of verbal aggression including screaming, making verbal sexual advances, and cursing or verbal aggression (items 22-24).
  • At least one failed pharmacological intervention to manage behavioral symptoms
  • Medically stable for safe administration of ECT verified by standard physical examination, urinalysis and serum chemistries and brain imaging when clinically indicated
  • Comprehension of English language
  • Authorized legal representative able and willing to give informed consent
  • Age 40 and above

Exclusion Criteria8

  • Current diagnosis of co-morbid delirium, measured by the Confusion Assessment Measure (CAM) and by clinical diagnosis
  • Diagnosis of vascular dementia due to stroke, based on:
  • History consistent with abrupt onset and step-wise progression of cognitive and functional decline
  • MRI scan within the past 12 months demonstrating evidence of hemorrhagic and embolic stroke
  • Physical and neurologic examination consistent with current or prior stroke
  • Lifetime or current diagnosis of Schizophrenia, Bipolar Disorder or Schizoaffective Disorder
  • Active substance use disorder within past 6 months
  • Treatment with ECT or other neurostimulation therapies (e.g., TMS or vagal nerve stimulation) within the past 3 months

Interventions

DEVICEElectroconvulsive Therapy (ECT)

Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.


Locations(5)

Emory Healthcare

Atlanta, Georgia, United States

McLean Hospital

Belmont, Massachusetts, United States

Pine Rest Christian Mental Health Services

Grand Rapids, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Northwell Health

Glen Oaks, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03926520


Related Trials